We use big data to develop lifesaving therapeutics.
Home of the world’s largest repository of single-cell sequencing data for neurodegenerative diseases.
The future of neurodegenerative medicine is at our fingertips.
Valted Seq is a discovery stage biopharmaceutical company spearheaded by world-renowned scientists Dr. Ted Dawson and Dr. Valina Dawson of Johns Hopkins University. The company was founded on the belief that a deeper understanding of neurodegenerative pathways is essential to develop precision therapeutics and identify novel biomarkers for some of the most challenging neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Valted Seq is part of the D&D Pharmatech/Neuraly family of companies, which works hand in hand with leading medical research institutions to advance groundbreaking healthcare innovations.
Do the most meaningful work of your career.
Valted Seq’s mission is to radically change, improve and prolong the lives of people suffering from some of the most devastating diseases. Our success requires the brightest minds. We would be thrilled if you had questions about opportunities or just wanted to chat to explore options.
“We expect this unprecedented repository of single-cell genomics, which Valted Seq will explore using advanced big data analytics, will accelerate progress towards better outcomes for patients.”
— Dr. Valina Dawson | Co-founder, Valted Seq
April 21, 2021
Valted Seq Announces Exclusive Right to Develop PAR and c-Abl Pathway Biomarker Assays for Diagnosis of Neurodegenerative Diseases
Read Article
Sept. 11, 2020
Newly Launched Valted Seq Working to Discover Disease Pathways, Biomarkers
Read Article
Sept. 9, 2020
D&D Pharmatech Announces Launch of Valted Seq Subsidiary Focusing on Discovery of Neurodegenerative Disease Pathways and Biomarkers
Read Article
Contact Us
Address
704 Quince Orchard Rd, Suite 320
Gaithersburg, MD 20878
Email
info@valtedseq.com